SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida. A live webcast of the presentation will be available in the investors section of the company’s website at www.sept ...

Core Insights - Septerna, Inc. has selected SEP-479 as its next-generation oral PTH1R agonist development candidate for hypoparathyroidism and is currently conducting a Phase 1 clinical trial for SEP-631 targeting MRGPRX2 for mast cell-driven diseases [2][3] - The company reported a robust financial position with cash, cash equivalents, and marketable securities totaling $561.6 million, expected to support operations at least into 2029 [1][13] Business Updates - SEP-479 demonstrated robust, dose-dependent increases in serum calcium and decreases in endogenous parathyroid hormone levels in a seven-day study in healthy cynomolgus monkeys, with plans to initiate a Phase 1 clinical trial in the first half of 2026 [7][3] - The ongoing Phase 1 clinical trial for SEP-631 is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics, with initial data expected in the first half of 2026 [4][2] - Septerna is advancing its TSHR NAM program aimed at developing a potential oral treatment for Graves' disease and thyroid eye disease [8] Financial Performance - Revenue for the quarter ended September 30, 2025, was $21.5 million, a significant increase from $0.2 million in the same quarter of 2024, driven by the amortization of the $195 million upfront payment from Novo Nordisk [13] - Research and development expenses were $24.3 million for the quarter, compared to $17.8 million in the same quarter of 2024, while general and administrative expenses rose to $7.1 million from $4.9 million [13] - The company reported a net income of $8.2 million for the quarter, a turnaround from a net loss of $20.5 million in the same quarter of 2024 [13]

Core Insights - Septerna, Inc. has appointed Dr. Keith Gottesdiener to its board of directors, who will chair a newly formed R&D Committee, bringing over 30 years of biotechnology experience [1][2] - Dr. Gottesdiener's expertise in advancing therapeutics and regulatory strategy is expected to support Septerna's lead programs and pipeline development [2] - The company is focused on GPCR drug discovery through its proprietary Native Complex Platform™, aiming to address unmet medical needs across various therapeutic areas [3] Company Overview - Septerna, Inc. is a clinical-stage biotechnology company specializing in GPCR therapies, with a strong team of experts and a diverse pipeline of oral small molecule drug candidates [3] - The company is advancing programs in endocrinology, immunology, inflammation, and metabolic diseases, both independently and in collaboration with partners [3] Leadership Background - Dr. Gottesdiener has held significant leadership roles, including President and CEO of Prime Medicine, Inc., and CEO of Rhythm Pharmaceuticals, Inc., where he oversaw the approval of setmelanotide for three obesity indications [2] - His previous experience includes 16 years at Merck Research Laboratories, where he was responsible for the approval of over 20 novel therapeutics and more than 200 IND submissions [2]

Core Insights - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery [1][2] - The company will participate in two upcoming investor conferences in September 2025, showcasing its commitment to engaging with investors [1] Company Overview - Septerna is advancing GPCR therapies to address significant unmet medical needs, utilizing its proprietary Native Complex Platform™ for drug discovery [2] - The company has developed a diverse pipeline of novel oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases [2]

Company Overview - Septerna, Inc. is a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, utilizing its proprietary Native Complex Platform™ to enhance GPCR therapies [3] - The company has developed a deep pipeline of oral small molecule product candidates targeting three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases [3] Upcoming Event - Jeffrey Finer, M.D., Ph.D., CEO and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 3:45 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website and will be archived for at least 30 days [2]